



Michael J. Rosenberg (left) has been appointed president and CEO of OPX Biotechnologies (Boulder, CO, USA), succeeding **Charles R. Eggert**, who is leaving to pursue other opportunities. Rosenberg had served as vice president of business development since 2009. He joined OPXBIO from Evergreen Energy, a cleaner coal technology company, where he was also vice president of business development.

“Mike’s depth of experience in accelerating product commercialization through strategic partnering, combined with his ongoing business development efforts at OPXBIO, ideally position him to lead the company as we move towards commercializing OPXBIO’s BioAcrylic Acid and fatty acid products,” says OPXBIO chairman Rob Chess. “The board looks forward to working with Mike in this new phase for the company.”

Juno Therapeutics (Seattle) has appointed **Hal Barron** to its board of directors. Barron is currently president of R&D at Calico. Previously, he served as executive vice president and chief medical officer at Genentech and Roche.

Selexis (Geneva) has promoted director of European business development **Marco Bocci** to vice president, European licensing and business development. Bocci joined Selexis in 2013 as the European director of sales and business development. Previously, he served as business development director at Quintiles Outcome.

Pfenex (San Diego) has announced the appointment of **Robin D. Campbell** to the company’s board of directors. He currently serves as chairman of the board of Aptitude Medical Systems. From 2004 to 2008, he was president and CEO of Naryx Pharma.



Epic Sciences (San Diego) has announced the appointment of **Michael Giske** (left) as chief information officer. Giske will lead the IT strategy and execution for the company’s diagnostics platform, including its

circulating tumor cell (CTC) technology. He was most recently director of IT strategy and architecture at Oracle. Previously, he was CEO and managing partner at KPMGS, a provider of IT solutions and services.

John Goetz has been named COO of Bio-Rad Laboratories (Hercules, CA, USA). Goetz has been with Bio-Rad for 40 years and has served in various capacities including division manager of quality systems and group operations manager. In 2000, he was appointed to head the clinical diagnostics group. In addition, **John Hertia** has been appointed executive vice president and president of the clinical diagnostics group, succeeding Goetz, and **Shannon Hall** has been named executive vice president and president of the life science group.

Advaxis (Princeton, NJ, USA) has appointed **David J. Mauro** as executive vice president, chief medical officer. He most recently served as executive director, section head oncology, clinical development at Merck & Co.

Kane Biotech (Winnipeg, Manitoba, Canada) has named **Mark Nawacki** to its board of directors, replacing **Richard Cherney** who is retiring from the board. Nawacki is a co-managing partner of Davies Ward Phillips & Vineberg. He previously served as executive vice president, business and corporate development of Paladin until September 2014.

Robert J. Perez has been appointed CEO of Cubist Pharmaceuticals (Lexington, MA, USA) effective January 1, 2015. He currently serves as Cubist’s president and COO. **Michael W. Bonney** is retiring from his current role as CEO on December 31, 2014 and will become nonexecutive chair of Cubist’s board of directors. Current board chair **Kenneth M. Bate** will become lead independent director.

Retrophin (New York) has placed founder and CEO **Martin Shkreli** on involuntary leave following alleged instances of stock-trading irregularities and other violations of securities rules. COO **Stephen Aselage** has been named interim CEO. In addition, CFO **Marc Panoff** and board member **Jeffrey Paley** have stepped down, and two new board members have been added: **Jeffrey A. Meckler**, a director of QLT Inc. and managing director of The Andra Group, and **Gary Lyons**, founder and former president and CEO of Neurocrine Biosciences.

Medical research charity MRC Technology (London) has named **John Stageman** as chair of its board of directors, succeeding **John Jeans**, who has served as chair for the last six years. Stageman has held a number of R&D senior management roles at AstraZeneca, from drug discovery through to global clinical development. He most recently served as vice president of UK science affairs before retiring in 2011.

Michael D. Step has been named CEO of Ritter Pharmaceuticals (Los Angeles). He was appointed to the company’s board of directors in 2011 and will continue to serve as a director. Company founder **Andrew Ritter**, who previously served as president and CEO, will now hold the title of president while continuing as a director. Step was most recently senior vice president of corporate development and a member of the executive committee of Santarus until its sale to Salix Pharmaceuticals in January.

Therapix Bio (Tel Aviv) has named **Jan Turek** as CFO. Turek joins Therapix with over 30 years’ experience in biotech and pharma executive leadership. He is currently a partner at TCG and was previously CEO of Biolex Therapeutics.

Revalesio (Tacoma, WA, USA) has appointed **Bert van den Bergh** as president. He previously spent 30 years with Eli Lilly & Company, where he served as president of neuroscience products, president of European operations and general manager for the United Kingdom and Germany.

R. Sanders Williams, currently the president of the nonprofit Gladstone Institutes and its Robert W. and Linda L. Mahley Distinguished Professor of Medicine, has been named to the Amgen (Thousand Oaks, CA, USA) board of directors.